Q1 Earnings Estimate for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for shares of Exelixis in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of $0.36 for the quarter, up from their prior forecast of $0.35. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.68 EPS and FY2025 earnings at $2.15 EPS.

A number of other equities research analysts have also recently commented on EXEL. Barclays increased their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Guggenheim reiterated a “buy” rating and set a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Royal Bank of Canada boosted their price target on Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Stock Performance

Shares of EXEL stock opened at $36.70 on Friday. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of 20.73, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis has a one year low of $20.14 and a one year high of $40.02. The company’s 50-day moving average is $35.71 and its 200 day moving average is $33.27.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Institutional Trading of Exelixis

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its holdings in Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after buying an additional 3,001,204 shares during the period. Norges Bank bought a new position in shares of Exelixis in the fourth quarter worth about $94,867,000. Caisse DE Depot ET Placement DU Quebec grew its position in shares of Exelixis by 330.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock worth $82,730,000 after purchasing an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after purchasing an additional 1,613,482 shares during the period. Finally, Voloridge Investment Management LLC purchased a new position in Exelixis in the 4th quarter worth approximately $30,321,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last three months. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.